MARIETTA, Ga., June 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today the presentation of new clinical data at the American Society of Colon and Rectal Surgeons 2017 Annual Scientific and Tripartite Meeting ("2017 ASCRS Annual Scientific Meeting"), showing that the use of AmnioFix, MiMedx's surgical dehydrated Human Amnion/Chorion Membrane (dHACM), around colorectal anastomoses can reduce post-operative leak rates.
Two posters entitled "Dehydrated Human Amnion/Chorion Membrane in Bowel Anastomoses" authored by Dennis Choat, MD, FACS, FASCR, and Emery Minnard, MD, are on display during the 2017 ASCRS Annual Scientific Meeting being held June 10 through June 14 in Seattle, Washington. Both data sets present the retrospective reviews conducted independently by each of Dr. Choat and Dr. Minnard in their separate studies on the use of MiMedx dHACM in colorectal resection surgery. Dr. Choat presented his data on Monday, June 12.
The independent studies conducted by Dr. Choat and Dr. Minnard involved different patient groups and population sizes that had colorectal resections. Both studies compared clinical results in patients who underwent colorectal resection surgery with and without the wrapping of the anastomoses with dHACM. Prior to Dr. Choat's adoption of dHACM anastomotic wrapping, his population of patients undergoing colorectal resections experienced an anastomotic average leak rate of 4.0%. After addition of dHACM anastomotic wrapping to his procedure, his average patient leak rate was significantly reduced to 1.21%. Similarly, Dr. Minnard's data also showed a clinically meaningful improvement in average leak rate from 5.0% in prior patients without the adoption of dHACM anastomotic wrapping to 1.35% after adoption of the dHACM to enhance healing at the anastomosis.
Drs. Choat and Minnard concluded in their respective studies that dHACM appears to significantly reduce the number of anastomotic leaks in colon resection surgery; and may reduce the length of hospital stay and/or need for readmission. Additionally, Drs. Choat and Minnard each concluded that a material like dHACM that can act as a barrier, reduce scar tissue formation, modulate inflammation and enhance healing is highly desirable to surgeons performing colorectal surgery. They each also concluded that the inherent properties of amniotic membrane, such as being immune privileged and having the ability to modulate inflammation and reduce scar tissue formation, present significant therapeutic potential in wound healing, tissue repair and regenerative surgery settings.
Parker H. "Pete" Petit, CEO, said, "Anastomotic leaks are one of the most serious complications following gastrointestinal surgery. We are very pleased with the impact AmnioFix has had for many patients undergoing bowel resections. These studies add to our growing body of evidence showing how MiMedx placental tissues can improve outcomes in surgical procedures by enhancing healing and helping to reduce serious complications such as anastomotic leaks. We applaud both Dr. Choat and Dr. Minnard on their commitment to patient care and advancing the clinical evidence in this challenging area."
Chris Cashman, Executive Vice President and Chief Commercialization Officer, added, "Anastomotic leaks increase the potential postoperative morbidity and mortality rates in addition to the overall cost of post-operative patient care. In a published study article entitled 'The Burden of Gastrointestinal Anastomotic Leaks: an Evaluation of Clinical and Economic Outcomes,' the study authors determined that after factoring in re-admissions, the average incremental length of stay and the average incremental hospital cost increased by up to 9.5 days and $28,600, respectively. The respective data presented by Drs. Choat and Minnard regarding the use of dHACM in colorectal surgery represent an important step forward in improving both clinical outcomes for patients who undergo colorectal resections, as well as the potential to reduce the economic burden associated with serious post-operative complications such as leaks."
Dr.Choat's poster can be found on the MiMedx website at the following link: https://www.mimedx.com/sites/default/files/Dennis%20Choat%20MD%20Poster%20ASCRS%20June%202017.pdf
Dr.Minnard's poster can be found on the MiMedx website at the following link: https://www.mimedx.com/sites/default/files/Emery%20Minnard%20MD%20Poster%20ASCRS%20June%202017%20.pdf
MiMedx® is a biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 900,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the significance of case study results, and the Company's belief that the use of dHACM in colorectal resections for enhanced healing of a surgical wounds can result in a reduction of the incidence of anastomotic leaks and their clinical and economic burden. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include individual patient and doctor experiences may vary, other case studies may have different or less favorable results, the use of dHACM may not have an impact on the economic burden associated with anastomotic leaks or may have a negative impact, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2016 and its most recent 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-amniofix-data-showing-colorectal-anastomotic-leak-rate-reduction-presented-at-ascrs-meeting-300473357.html
SOURCE MiMedx Group, Inc.